Evidence map›Paper›PMID 40646592›Full record

ArticleAlzheimer's research & therapy2025

Cerebral small vessel disease in memory center patients with dementia with lewy bodies and Alzheimer's disease.

Giulia Bommarito, Alessandra Griffa, Patrik Michel, Caroline Hall, Chiabotti Paolo Salvioni, Silvia Pistocchi, Yasser Alemán-Gómez, Daniel Damian, Mario Jreige, John O Prior and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Giulia BommaritoLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland. giulia.bommarito@chuv.ch.
Alessandra GriffaLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland.
Patrik MichelStroke Center, Neurology Service, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
Caroline HallLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland.
Chiabotti Paolo SalvioniLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland.
Silvia PistocchiDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
Yasser Alemán-GómezDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
Daniel DamianLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland.
Mario JreigeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
Vincent DunetDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
Olivier RouaudLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland.
Patric HagmannDepartment of Diagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne (CHUV-UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
Gilles AllaliLeenaards Memory Center, Department of clinical neurosciences, Lausanne University Hospital and University of Lausanne (CHUV-UNIL), chem. de Mont-Paisible, 16, Lausanne, 1011, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCerebral small vessel disease (CSVD) is a common co-pathology in patients with dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). A comprehensive characterization of CSVD load in DLB and AD patients referred to a memory center is lacking.

methodsIn this retrospective study, we collected data from patients with a clinical DLB diagnosis or clinico-biological AD diagnosis, evaluated at our memory center. They were assessed for CSVD MRI features, including enlarged perivascular spaces (PVS), presence of cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HTNA). Differences in CSVD features between AD and DLB and across clinical stages were investigated. Regression models were used to evaluate the association between (i) cerebrovascular risk factors (CVRF) and HTNA, and (ii) CSVD features and cognition as expressed by Montreal Cognitive Assessment (MoCA).

resultsWe included 71 DLB (76.8 ± 7.4 years old, 25 females) and 71 age- and sex-matched AD patients (and 75.2 ± 5.3 years old, 27 females). Probable CAA, according to current Boston 2.0 criteria, was observed in 22.5% of DLB and 35.2% of AD patients, while any (probable + possible) CAA rate was higher in the two groups (71.8% and 91.5%, respectively). A moderate/severe HTNA was present in 45% of DLB and 28.2% of AD patients. When comparing the two groups, DLB presented with higher HTNA score (p =.012), while AD patients had higher prevalence of any CAA (p =.002). Patients with DLB had a greater PVS burden in the basal ganglia (p =.011) and centrum semiovale (p =.004) and higher number of deep microbleeds (p =.004). Certain HTNA-related features were more pronounced at dementia stage, with respect to mild cognitive impairment. No association was observed between CVRF and HTNA. Regarding the association between CSVD and cognition, only deep microbleeds count was related to MoCA in DLB patients. DISCUSSION: DLB or AD patients present with high CSVD burden and differ in terms of features and subtype. Patients with DLB present with increased HTNA, PVS load and deep microbleeds, while patients with AD present with a higher any CAA prevalence. CSVD might impact global cognition.

Indexed as

Alzheimer DiseaseCerebral Small Vessel DiseasesLewy Body DiseaseAgedAged, 80 and overBrainCerebral Amyloid AngiopathyFemaleHumansMagnetic Resonance ImagingMaleMental Status and Dementia TestsRetrospective StudiesADAlzheimer’s diseaseCerebral small vessel diseaseCSVDDementia with lewy bodiesDLBPerivascular spaces

Identifiers

PMID40646592
PMCPMC12254957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.